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Leaver et al. used fluorinated steroids as
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biosynthesis and growth of Trypanosoma
brucei. This study demonstrates the
potential of treating neglected tropical
diseases with fluorinated analogs of a
crucial enzyme in protozoan parasites
absent from the human host.
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Trypanosoma brucei, the causal agent for sleeping
sickness, depends on ergosterol for growth. Here,
we describe the effects of amechanism-based inhib-
itor, 26-fluorolanosterol (26FL),whichconverts in vivo
to a fluorinated substrate of the sterol C24-methyl-
transferase essential for sterol methylation and func-
tion of ergosterol, and missing from the human host.
26FL showed potent inhibition of ergosterol biosyn-
thesis and growth of procyclic and bloodstream
forms while having no effect on cholesterol biosyn-
thesis or growth of human epithelial kidney cells.
During exposure of cloned TbSMT to 26-fluorocho-
lesta-5,7,24-trienol, the enzyme is gradually killed
as a consequence of the covalent binding of the in-
termediate C25 cation to the active site (kcat/kinact =
0.26 min1/0.24 min1; partition ratio of 1.08),
whereas 26FL is non-productively bound. These re-
sults demonstrate that poisoning of ergosterol
biosynthesis by a 26-fluorinatedD24-sterol is a prom-
ising strategy for developing a new treatment for
trypanosomiasis.
INTRODUCTION
The parasitic protozoan, Trypanosoma brucei, the etiological
agent for sleeping sickness, is naturally transmitted by the
blood-sucking tsetse fly (Glossina) (Van Den Abbeele et al.,
1999). Sleeping sickness is endemic in 36 African countries,
with 300,000 new cases and approximately 10,000 deaths per
year, andmore than 60million people at risk (World Health Orga-
nization, 2013). Disease development of human African trypano-
somiasis (HAT) is marked by an initial hemolymphatic stage,
which can progress to the CNS after the parasite crosses the
blood-brain barrier, yielding a late meningoencephalitic stage
that is deadly. Current chemotherapy options are stage-specific
and limited to stage-1 drugs (pentamidine and suramin) and1374 Chemistry & Biology 22, 1374–1383, October 22, 2015 ª2015 Estage-2 drugs (melarsoprol and eflornithine), and are compro-
mised by adverse side reactions, diminishing efficacy in several
geographical regions, and complexity of use (Barrett, 2010; Fer-
rins et al., 2013). Many of these drugs have been in use since the
1950s. On the whole, there is a pressing need to develop chemo-
therapeutics with novel mechanisms of action for the treatment
of life-threatening HAT infections.
Phylogenomic and chemical studies reveal distinct differences
in the genetic andmetabolite compositions of protozoan and an-
imal sterol metabolomes, which produce ergosterol and choles-
terol, respectively (Fugi et al., 2014; Nes, 2011; Roberts et al.,
2003). This diversity in sterol metabolism between T. brucei
and its human host has presented the intriguing possibility that
protozoan biochemistry could be selectively inhibited. Indeed,
our recent discovery shows there is an essential requirement
for hormonal levels of ergosterol to ‘‘spark’’ (signal) cell prolifer-
ation of T. brucei bloodstream forms (BSF) (Figure 1A), which
cannot be satisfied solely by cholesterol salvaged from the
host (Haubrich et al., 2015). These studies, plus the demonstra-
tion that inhibitors shown to block enzymes in the post-squalene
segment of ergosterol biosynthesis pathway prevent growth of
many protozoan parasites without an effect on cultured animal
cells (Gigante et al., 2009; Gros et al., 2006; Gunatilleke et al.,
2012; Lepesheva et al., 2007; Lepesheva and Waterman, 2011;
Lorente et al., 2004; Lovieno et al., 2014; Porta et al., 2014; Rah-
man and Pascal, 1990; Zhou et al., 2007) confirms our idea.
Consequently, there is an effort under way to probe ergosterol
biosynthesis targets with the aim of identifying new drugs to treat
specific neglected tropical diseases considered ergosterol
dependent.
Most of the earlier research on lead development for new
drugs resulted from the accidental observation of the biological
effects of natural products or from screening organic com-
pounds (Pink et al., 2005), whereas little attention has been
directed toward druggable enzymes of ergosterol biosynthesis.
In our search for effective ergosterol biosynthesis inhibitors to
treat protozoan infections, we were guided by the seminal
work on the repurposed drug eflornithine (DL-a-difluoromethy-
lornithine), a fluorinated substrate mimic of L-ornithine decar-
boxylase (ODC) shown to control flux through the polyamine
pathway, associated with cell growth and differentiation.lsevier Ltd All rights reserved
AB
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Figure 1. Overall Biosynthetic Pathway from Lanosterol to Ergosterol
(A) Functional aspects of different sterols. ERG, ergosterol.
(B) C24-methylation reaction scheme showing conversion of D24-substrate to a kill or turnover methyl product. Formation of these alternative outcomes requires
preliminary formation of a C24-methyl high-energy intermediate (HEI) cation.Mechanism-based inactivation of this enzyme proceeds via pyr-
idoxal phosphate-assisted decarboxylative elimination of fluo-
ride to produce a fluorinated Michael acceptor that is captured
by an active site cysteine residue (Andrews et al., 2014; Poulin
et al., 1992). In addition, inhibition of this enzyme in Gambian
sleeping sickness interferes with spermidine formation that
thereby produces parasite death (Heby et al., 2003). Importantly,
a contributing factor to the treatment success of eflonithine is the
significant differences in sensitivities of the parasite and animal
ODC to the inhibitor.
Recently, the steroidal inhibitor 14a-methylenecyclopropyl
D7-24(25)-dihydrolanosterol (MCP), fashioned to complex with
T. brucei sterol 14a-demethylase (14-SDM) and prevent cell
growth, has emerged as an alternative to medical azoles to
disrupt ergosterol homeostasis (Hargrove et al., 2012). The pro-
posed mechanism of action of MCP to interfere with sterol 14-
demethylation by irreversible binding to TbSDM differs from
that of azoles, which interact with the CYP51 enzyme as adduct
to the heme iron as well as noncovalently with the substrate-
binding site (Hargrove et al., 2011). An entirely analogous strat-
egy is well established in the area of aromatase inhibitors, where
suicide substrates of the estrogen biosynthetic pathway en-
zymes have been shown to be potent drugs in breast cancer
therapy (Bruegemeier et al., 2005). Azoles, however, suffer the
disadvantage of being general P450 inhibitors, their efficacy de-
pending on a greater affinity for the protozoan P45014SDM versus
the mammalian P45014SDM, and some of them can bind concur-
rently to P450 enzymes and related steroid side-chain metabo-
lizing enzymes showing a lack of specificity (Lepesheva and
Waterman, 2011). A more exact approach in the design of anti-
parasite agents has been the development of phyla-specific
steroidal inhibitors of sterol C24-methyltransferase (24-SMT)
catalysis, such as 25-azalanosterol. These high-energy interme-
diate analogs can block ergosterol biosynthesis and halt cell
growth by specifically inhibiting sterol methylation, which does
not occur in animals (Liu and Nes, 2009).Chemistry & Biology 22, 1374–1Given the key role of fluorinated small molecules as pharma-
cological agents in the regulation of cholesterol biosynthesis
and metabolism (Trzaskos et al., 1993), and the demonstration
that fluorinated cholesterols can replace cholesterol as a mem-
brane insert and support the growth of fungal sterol auxotrophs
(Kauffman et al., 2000; Matsumori et al., 2008; Zundel et al.,
1989), there has been remarkably little work reported on the in-
fluence of fluorinated compounds in ergosterol production and
processing by protozoa. In our previous work, we reported fluoro
substituents attached to the cycloartenol side chain at C24 or
C26 that do not affect binding affinities to soybean 24-SMT
(EC 2.1.1.143) as a consequence of the steric similarity between
a fluorine and hydrogen atom (Patkar et al., 2013; Wang et al.,
2008). On the other hand, the fluorine can exert a strong influ-
ence on the electronic environment that thereby affects interme-
diate cation formation and timing of the C24-methylation reac-
tion. These effects promote partitioning toward covalent
modifications over turnover catalyzed by 24-SMT (i.e., route
1/2/4 versus 5, 6, or 7, Figure 1B). This property of enzyme
inactivation for ergosterol biosynthesis inhibitors could, unlike
the ammonium side chain-containing sterols or medical azoles,
disrupt ergosterol homeostasis without markedly affecting the
sterol composition of treated cells, forming the basis for a safe
yet potent drug that could be used in combination therapy with
existing therapeutics.
In this article, we provide metabolite differences and biological
effects together with mechanistic understanding for a novel
class of fluorinated trypanocide evaluated using cultures of
T. brucei and human epithelial kidney (HEK) cells and the cloned
TbSMT. We were interested in identifying a highly efficient sub-
strate-mediated inhibitor of TbSMT (EC 2.1.1.41) that in its cova-
lent inactivation affords a low partition ratio whereby relatively
few of the intermediate molecules formed are necessary to kill
the enzyme, while those that convert to methyl product leave
the active site and become inert metabolites. The results re-
ported here provide a new route to fluorinated functionality for383, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1375
Figure 2. Growth Response of Trypanosoma brucei Procyclic and
Bloodstream Forms to Increasing Concentrations of 26FL
(A and B) Growth curves were performed in triplicate for (A) procyclic form
(PCF) and (B) bloodstream form (BSF) full-grownmedium (FGM) by conducting
three independent experiments described in the Experimental Procedures;
error bars are not shown because, in most cases, they approximate the data
symbols.‘‘suicide substrate’’ poisoning of an essential enzyme in ergos-
terol biosynthesis. We also observed that 26-fluorolanosterol
(26FL) is a steroidal prodrug that produces growth inhibition in
the low micromolar range complementary to the previously
described use of fluorinated substrate-based inhibitors that
target the enzyme that controls flux through the polyamine
pathway in T. brucei.RESULTS
26-Fluorolanosterol Inhibits Growth of T. brucei Cells
but Not HEK Cells
To assess the growth effect of a fluorosterol designed as a
mechanism-based inhibitor of TbSMT, cell-based studies
were performed with 26FL. The compound added at various
concentrations to the medium of T. brucei procyclic form
(PCF) and BSF, and HEK cell cultures, generated median inhib-
itory concentration (IC50) values of approximately 3 mM for PCF
and 16 mM for BSF (Figure 2) while 26FL had no effect on HEK
cell growth up to 100 mM (data not shown). The dose of 26FL
causing 50% cell growth inhibition (IC50) correlates with a mod-
erate therapeutic index (ED50HEK/ED50bloodstream) of 6.2, with
cells remaining viable even at the IC99 value of the drug (Hau-
brich et al., 2015).1376 Chemistry & Biology 22, 1374–1383, October 22, 2015 ª2015 EExploitation of Metabolic Differences
To determine the underlying biochemistry responsible for the dif-
ferences in growth response to 26FL, we considered the inhibitor
to block the target enzyme, 24-SMT, in the ergosterol biosyn-
thesis pathway. In agreement with our proposal, treated PCF
showed a dose-dependent drop in ergosterol content that corre-
sponds to zero-line growth inhibition equivalent to the inoculum.
Gas chromatography-mass spectrometry (GC-MS) analysis of
neutral lipids of PCF-treated cells at the IC50 of 26FL show a
loss of ergosterol at relative retention time to cholesterol
(RRTc) of 1.11 (Figure 2A), otherwise the sterol profile is similar
to the previously reported control (Lepesheva and Waterman,
2011). In our GC conditions, ergosterol and cholesta-5,7,24-tri-
enol effectively co-elute; however, ergosterol can be detected
in the mass spectrum at approximately 1%–3% the sterol
mixture or at even lower concentrations at approximately 0.5%
total sterol through selected ion monitoring for appropriate ions
(e.g., M+, 396 andM+ 33, 363 [-CH3-H2O]) (Zhou et al., 2007) (Fig-
ure S1). At the IC50 of 26FL, trace amounts of three new fluori-
nated metabolites (<1% total sterol) were evident at the baseline
of the chromatogram. When the drug is added at the IC90 value,
the fluorinated compounds accumulate (5% of total sterol) to
greater levels in the sterol mixture than at IC50 values, which
allow for an interpretation of theirmass spectra; two of themelute
on the front and back sides of the peak corresponding to an
ergosterol isomer ergosta-5,7,25(27)-trienol (RRTc 1.17, M+
396), and a third compound elutes late in the chromatogram
with a mobility typical of an ‘‘oxysterol.’’ Based on knowledge
of chromatographic and mass spectral identification of the
endogenous metabolites of the ergosterol biosynthesis pathway
and oxysterols that contain a hydroxyl group in the side chain,
coupled with the GC retention factor calculated for a 26-
hydrogen to 26-fluorine moiety of 1.06 (Nes et al., 1988, 2012;
Patkar et al., 2013; Xu et al., 1988), two new fluorinated steroidal
‘‘monols’’ were identified as 26-fluorocholesta-5,7,24-trienol
(26-FCT) (RRTc 1.16, M+ 400) and 26-fluoroergosta-8,25(27)-di-
enol (RRTc 1.21, M+ 414, M+-HF, 396; M+-CH3-HF, 381, M
+-
H2O-HF-2H; Figures 3B-1 and 3B-2, respectively). Mass spectra
of the fluorinated sterol metabolites contain contaminant ions
from ergosta-5,7,25(27)-trienol (Figure S1B). A third new com-
pound eluting at RRTc 1.39 (M+ missing, M+-HF, 414; M+-
H2O-HF, 378; Figure 3B-3) is tentatively identified as the steroidal
‘‘diol’’ 26-fluoro 3,25-dihydroxyergost-8-enol. A similar enzyme-
generated diol with the cycloartenol nucleus was identified from
incubation of 26-fluorocycloartenol with soybean 24-SMT (Pat-
kar et al., 2013). The parent compound 26FL was also present
in the fluorinated sterol mixture as a minor component in the
GC tail corresponding to the diol at RRTc of 1.40 (M+ 444). The
identification of an apparent abortive product of the C24-methyl-
ation reaction in the form of a ‘‘diol’’ (Figure 3C, *-3) is consistent
with the intermediate cation intercepted by an active site nucle-
ophile generating enzyme inactivation (Patkar et al., 2013). Thus,
most of the 26FL accumulated by cells (<95%) is converted to
26-fluorinated metabolites, and the apparent inactivation of
TbSMT by enzyme-activated 26-fluorozymosterol is the likely
reason for blocked zymosterol conversion to ergosta-8,25(27)-
dienol and loss of ergosterol in cells.
Sterol analyses were conducted on neutral lipids of HEK cells
cultured in the presence and absence of 26FL (at 100 mM).lsevier Ltd All rights reserved
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Figure 3. GC-MS Analysis of Neutral Lipids from 26FL-Treated Procyclic Forms at IC50 Concentration of Inhibitor
(A) Total ion chromatogram of total sterols isolated from treated cells, with inset showing the mass spectrum corresponding to the GC peak of cholesta-5,7,24-
trienol (M+ 382) and ergosterol (M+ 396).
(B) B-1 and B-2 represent the mass spectra from GC peaks on the front and back side of the peak corresponding to cholesta-5,7,24-trienol at the IC90 con-
centration of inhibitor. B-3 represents the GC peak eluting late at RRTc 1.39 at the IC90 concentration of the inhibitor.
(C) The uncommon ergosterol biosynthesis pathway in T. brucei, with structures marked by an asterisk detected in the GC-MS analysis of 26FL treatments.GC-MS analysis of the neutral lipids of control (Figure 4A) and
treated cells (Figure 4B) showed exclusively cholesterol or
cholesterol accompanied by a set of 26-fluorosterol com-
pounds that represent approximately 40% total cellular sterol;
of the 26FL accumulated by cells, approximately half of it con-
verts to inert products. Based on the 26H to 26F retention fac-
tor for standards bearing a 26-hydrogen atom (lanosterol RRTc
1.31, M+ 426) and 26-fluorine atom (26FL RRTc 1.41, M+ 444;
Figure 4D, *-3) and comparison of the RRTc and mass spectra
(Figure 4C) of the 26-fluorosterol metabolites with the data es-
tablished for intermediates in the cholesterol biosynthesis
pathway (Nes, 2011), three metabolites detected in the treated
cells are new (Figure 4C, compare with endogenous sterol
mass spectra shown in Figure S2); 26-fluoro 4,4,-dimethyl cho-
lesta-8,24-dienol (RRTc 1.46, M+ 430; Figure 4D, *-4), 26-fluoro
4a-methyl cholesta-8,24-dienol (RRTc 1.26, M+ 416; Figure 4D,
*-2), and 26-fluoro cholesta-8,24-dienol co-eluting with cho-
lesta-7,24-dienol (RRTc 1.12, M+ 402 and M+ 384, respectively;
Figure 4D, *-1). Selective ion monitoring for molecular weights
of compounds that could represent sterols with C24-reduced
side chains (e.g., M+ 404 for 26-fluorocholesterol) failed to
reveal any additional fluorosterol metabolites. It is worth
mentioning that as in the 26FL-treated PCF incubation where
ergosta-8,25(27)-dienol accumulates, in the 26FL-treated HEK
cells olefinic sterols with a double bond in the side-chain
D24(25) position accumulate as well, which suggests a general
blockage of sterol reductase enzymes in these cultures. The
accumulation of fluorinated sterols in HEK cells appears toChemistry & Biology 22, 1374–1have no apparent harmful effect on growth, as expected (Zun-
del et al., 1989).
26-Fluorolanosterol Is a Reversible Inhibitor of TbSMT
Inhibitor dissociation constants (Ki) for C24-methylation of 26FL
were based on initial reaction rate measurements with varied in-
hibitor concentrations (Nes et al., 2003, 2012). The fluorinated
analog, 26FL, was incubated with cloned TbSMT under the stan-
dard reaction conditions used previously for the conversion of
zymosterol to methyl product. As judged by GC-MS analysis,
there is no product formation by TbSMT catalysis (Figure 5A)
even after prolonged incubation or with different concentrations
of protein up to 5 mg. This substrate, although not productively
bound, exhibited a Ki value of 85 mM with competitive-type ki-
netics relative to zymosterol (Figure 5B), similar to the previously
reported Ki value of lanosterol of 126 mM (Haubrich et al., 2015).
Substrate protection is evident from the kinetics, whereby addi-
tion of analog slows down the rate of enzyme inhibition while
addition of substrate overcomes the inhibition by the analog.
These results and the active conversion to metabolite following
uptake by cells indicate that 26FL itself is not likely to be respon-
sible for the growth inhibition.
Products of the TbSMT C24-Methylation with
26-Fluorocholesta-5,7,24-Trienol
To determine whether the 26FL metabolite 26-fluorozymosterol
could show suicide substrate properties toward TbSMT in a
cell-free system, we considered preparing 26-fluorozymosterol383, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1377
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Figure 4. GC-MS Analysis of Neutral Lipids From 26FL-Treated HEK Cells
(A) Total ion chromatogram of HEK control.
(B) Total ion chromatogram of 26FL-treated cells. Peak with an asterisk is a non-steroidal compound.
(C) Mass spectra for the four 26-fluorosterols detected in the chromatogram and labeled in peaks C-1 to C-4.
(D) The conical pathway for conversion of lanosterol to cholesterol, with compounds marked with an asterisk corresponding to 26-fluorosterol metabolites
shown in (B).as a substrate. However, due to a paucity of zymosterol for the
synthetic work, another analog was chosen to test with the
enzyme. Because cholesta-5,7,24-trienol shows competency
similar to that of zymosterol in acceptance by TbSMT (Lepe-
sheva andWaterman, 2011), we reasoned the fluorinated analog
of cholesta-5,7,24-trienol could be prepared from commercially
available ergosterol and tested as an alternative analog. 26-FCT
paired with S-adenosyl-L-methinione (SAM) was incubated with
cloned TbSMT. GC-MS analysis (Figure 5C) showed that the
early-eluting compound at 18 min possesses a D5,7 system
(ions atm/z 128, 143, 157, 158, and 159) similar to the substrate
(Figure S3) and C24-methyl side chain (ions atm/z 414 [M+], 400,
380, 367, 349) typical of a methylated fluorosterol. The
late-eluting compound at approximately 21.9 min also contained
a D5,7 system (ions at m/z 128, 143, 157, 158, and 159) and
a C24-alkylated side chain with a hydroxyl group (ions at
m/z 432 [= M+ missing], 412, 400, 365 and 347); these
enzyme-generated products correspond to 26-fluoroergosta-
5,7,25(27)-trienol and 26-fluoro 3,25-dihydroxyergosta-5,7-di-
enol, respectively (Figure 5D). The percent conversion of
fluorinated analog to methyl product is approximately 25%while
the ratio of C24-methyl turnover product to C24-methyl abortive
product (Figure 1B) is approximately 8. The identification of a key1378 Chemistry & Biology 22, 1374–1383, October 22, 2015 ª2015 Eabortive product (as the fluorinated diol), suggesting that the
ternary complex is arrested following formation of the first
high-energy intermediate, agrees with the proposed reaction
steps of sterol C24-methylation catalyzed by TbSMT outlined
in Figure 1B. It is noteworthy in the total ion current chromato-
gram in Figure 3A that the retention factor for the 26-fluoro-25-
hydroxy group (sterol 2 = RRTc 1.29) versus 26-fluoro-D25(27)
group (sterol 3 = RRTc 1.50) of 1.16 determined in the enzyme
assay with 26-fluorocholesta-5,7,24-trienol matches the reten-
tion factor of 1.16 for the same side-chain pair in 26-fluoro ergo-
sta-8,25(27)-dienol (RRTc 1.21) and 26-fluoro 3,25-dihydroxyer-
gosta-8-enol (1.39) identified in the whole-cell studies from
incubation of 26FL. The substrate analog evidently was capable
of uncoupling the reaction sequence catalyzed by TbSMT af-
fording the production of the corresponding steroidal diol, the
abortive product representative of the methyl intermediate
bound to the enzyme.
Determination of Kinetic Parameters
To assess the relative rate of enzyme-catalyzed methylation of
26-FCT versus zymosterol, both substrates were examined in
the linear range of enzymatic activity (5–150 mM) with the same
lysate preparation of recombinant enzyme. The fluoroanalog islsevier Ltd All rights reserved
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Figure 5. Enzyme-Generated Product Distributions and Kinetic Analyses of 26FL and 26-Fluorocholesta-5,7,24-Trienol Incubated with
TbSMT
(A) Total ion chromatogram of 26FL incubated with TbSMT.
(B) Lineweaver-Burk plot of 26FL inhibition of TbSMT activity.
(C) Capillary GC separation of methylated products synthesized from 26-fluorocholesta-5,7,24-trienol (26-FCT) by TbSMT.
(D) Corresponding structures of products shown in (C).
(E) Lineweaver-Burk plot of 26-FCT inhibition of TbSMT activity.
(F) Time-dependent inactivation of TbSMT by 26-FCT. Values plotted are the mean of duplicate determinations, which varied by less than 5%.methylated at approximately 9% the rate of zymosterol conver-
sion to ergosta-8,25(27)-dienol while yielding similarKM values of
25 ± 2 mM, comparable with our previous finding of aKM of 47 mM
for zymosterol and a KM of 25 mM for cholesta-5,7,24-trienol,
respectively (Liu et al., 2011; Zhou et al., 2006). Using a concen-
tration of 50 mg of native tetramer TbSMT approximated from the
SDS-PAGE gel of the enzyme preparation reported previously
(Zhou et al., 2006), the kcat values are estimated for 26-fluorocho-
lesta-5,7,24-trienol of 0.26 min1 compared with an estimated
kcat for zymosterol of 2.88 min
1, which is the same value as
before (Zhou et al., 2006). However, these turnover numbers
are approximately an order of magnitude greater than our previ-
ously reported value of 0.6 min1. In the latter case, the enzyme
was purified to homogeneity using a series of chromatographic
steps that involve anion-exchange columns (Zhou et al., 2006).
We tracked down the observed differences in catalytic compe-
tence and determined that they arise from the allosteric capabil-
ities of the enzyme operating in its native tetrameric form. Previ-
ously, we showed sigmoidal behavior of the pure enzyme toward
SAM (Nes et al., 1998). Now, we discovered that ATP bound to
the 24-SMT in pre-Q column preparations is released from the
active form during the purification procedure involving a Q-col-
umn chromatography step. Importantly, ATP at physiological
concentrations of 400 mM (Rodriguez and Parks, 1981) is a pos-
itive allosteric effector of cloned yeast 24-SMT and TbSMT activ-Chemistry & Biology 22, 1374–1ity, and restores completely the dramatic loss of enzyme activity
following Q-column chromatography (Marshall, 2001; and
W.D.N. and P.P., unpublished data). When cyclic AMP is added
to fungal cultures, the effect on ATP levels is associated with an
increase in ergosterol, presumably by activation of 24-SMT (Sar-
dari et al., 2003).
The product outcome from incubation of 26-FCT with TbSMT
showed reaction with SAM, and that the substrate analog binds
specifically to the active site. In addition, the kinetic behavior
shows that binding is almost as tight as that of the natural sub-
strate. Finally, replacing the C26 hydrogen in the zymosterol sys-
tem by fluorine retards the rate of C24-methylation, a reaction
known to proceed throughmultiple carbonium high-energy inter-
mediates to generate a single 26-fluoro abortive product. Thus, it
is quite possible that the coupled methylation and deprotonation
reactions catalyzed by TbSMT are discrete steps (Figure 1B),
whereas the same reaction catalyzed by the yeast 24-SMT oper-
ates in a concerted manner to produce a single D24(28) product
(Nes et al., 1998).
Further evaluation of 26-FCT as an analog for TbSMT was
based upon inhibition kinetics of 26-FCT against varying con-
centrations of zymosterol and fixed amounts of SAM using an
Escherichia coli preparation of the cloned enzyme. The double-
reciprocal plot of sterol methylation activity in the presence of
several concentrations of the fluorinated compound is shown383, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1379
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Scheme 1. Kinetic Schemes for the Interaction of TbSMT with Substrate Analogs
In (1), binding of enzyme (E) and D24-sterol substrate (S) is followed by enzyme catalysis with formation of methyl product (P). In (2), inhibitor (I) binds to enzyme
followed by activation via methylation (E - I*), and this intermediate can partition along path b and dissociate from the active site (E + IP*) or enter into path a and
irreversibly bind to the enzyme (E - I*).in Figure 5E. The data clearly indicate that the sterol is a compet-
itive inhibitor of the sterol methylase with respect to zymosterol,
showing a Ki of 75 mM. These data and that of product distribu-
tions from incubation with 26-FCT are consistent with the obser-
vation of accumulation of 26-fluoroergosta-8,25(27)-dienol in
treated cells. Thus, the notion that 26-fluorozymosterol is a sub-
strate mimic of zymosterol is confirmed by kinetic studies as well
as by metabolic conversions catalyzed by TbSMT.
Inactivation of TbSMT
Stable metabolites of 26FL did not inhibit TbSMT through a
reversible mechanism of inhibition. To assess the alternative irre-
versible mechanism of inhibition, we performed time-course
experiments using the cloned enzyme, which confirmed inacti-
vation accompanying the methyl intermediate formation with
half-maximal values for each occurring within 10 min (Figure 5F).
TbSMT activity declined by a pseudo-first-order process with a
half-life of 2.82 min1. The rate of inactivation of TbSMT was
saturable, with a maximum rate of inactivation, kinact, of 0.24 ±
0.01 min1 and a Ki of 89 mM, similar to that reported from the
steady-state Ki determinations reported in Figure 5E. These
values compare favorably with the kinetic parameters for the
normal substrate zymosterol. As expected, no inactivation
occurred when the incubations were carried out with sterol
only, consistent with absolute dependency of the co-substrates
for the reaction to generate covalently bound product
(Figure 1B).
DISCUSSION
Drug discovery for neglected tropical diseases falls into two
broad categories of molecular target-based and phenotypic ap-
proaches (Gilbert, 2013). Significant problems with neglected
tropical disease drug resistance include specificity and variant
mechanisms of resistance (Barrett et al., 2011; Chitanga et al.,
2011). These overarching problems need to be addressed for
any single compound to treat trypanosomiasis patients success-
fully. In the search for the next generation of anti-parasitic
agents, work on trypanosome sequences coupled with
biochemical investigations has pinpointed the sterol C24-meth-
yltransferase in the ergosterol biosynthesis pathway as a poten-
tial drug target. The substrate specificity of this crucial catalyst1380 Chemistry & Biology 22, 1374–1383, October 22, 2015 ª2015 Ereveals limited steroidal modifications that could be processed
by the enzyme. Nonetheless, structure-activity analyses of a
range of steroidal inhibitors incubated with 24-SMTs across
kingdoms provide the foundation for a tractable chemical start-
ing point. It has been demonstrated that substrate mimics
compete with the natural acceptor of 24-SMT for a common cat-
alytic site, and may occur with reversible inhibitors (azasterols)
as enzyme-bound transition state analogs or with irreversible in-
hibitors (fluorinated olefins) as enzyme-bound abortive interme-
diates. Whichever mechanism applies to the steroidal inhibitor
in vitro, it is clear that complete blockage of 24-SMT activity
by these compounds can offer a proof of principle for such
enzyme-targeted approaches. When suicide substrates
compared with tight-binding steroidal inhibitors of 24-SMT
show relevant differences in their effects on ergosterol biosyn-
thesis in treated cells, this could represent sequence-specific
recognition in the formation of a covalent complex, the basis
for phyla-specific inhibitors. Criteria for anti-parasite hits, leads,
and drug candidates in the design and testing of new enzyme in-
hibitors to block TbSMT in T. brucei have been met by our test
analogs in this and previous studies; i.e., the compound is active
with IC50 of%10 mM, active in vivo against parasites at a dose of
%100mg/kg, and not overly toxic in animals at efficacious doses
such that analogs can be obtained (Pink et al., 2005).
Preferential inhibition is gained in the suicide substrate
approach to enzyme inactivation in ergosterol biosynthesis,
which exploits analog specificity of TbSMT. The inhibition con-
stant Ki for a substrate analog describes its level of specificity
and the reversible equilibrium between enzyme and inhibitor
for the initial inhibitor-binding step; Kdiss is the dissociation con-
stant of enzyme-inhibitor complex (E∙I), I is inhibitor concentra-
tion, S is substrate concentration, and P the product concentra-
tion, while kcat describes the catalytic turnover number and kinhib,
expressed by the kinact constant, describes the time-dependent
rate of enzyme inactivation (Walsh, 1984) (Scheme 1).
Mechanistically, for 26-fluorinated analogs to act as an irre-
versible inhibitor the compounds should serve as substrates of
the Michaelis complex and convert to a methylated intermediate
cation (I*) similar to the processing of zymosterol by TbSMT. The
resulting fluorinated intermediate has the ability to capture an
apoprotein residue through competing processes that involve
partitioning toward deprotonation and turnover (E + IP*) typicallsevier Ltd All rights reserved
of the natural substrate (path b) or inactivation (E - I*) character-
istic of the steroidal inhibitor (path a), as shown in Scheme 1. The
functional inhibition of the enzyme is determined by the relative
rates of each of these pathways and, in particular, the formation
of the E - I* species.
One example of the in vitro potency of sterol C24-methyltrans-
ferase inhibitors is through comparison via the ratios of their
KM/Ki values; thus, the larger the ratio the greater the competitive
inhibition. When tested against TbSMT, the 26-fluoro substituted
analogs exhibited KM/Ki ratios for 26FL of 25:85 (= 0.29) and for
26-FCT of 25:75 (= 0.33) (this study) compared with a KM/Ki ratio
for 25-azalanosterol of 47:0.039 (= 1,205) reported previously
(Zhou et al., 2006). While it is notable that the azasteroids are
three orders of magnitude greater in effectiveness than inhibitors
of cell-free TbSMT, they do not show a corresponding potency in
terms of in vivo growth inhibition of cultured T. brucei cells. Thus
26FL, like 25-azalanosterol, inhibits PCF growth at approxi-
mately 1 mM.
Another way to assess altered catalytic capacity of TbSMT to
fluorinated analog is through examination of both concentration-
dependent and time-dependent inhibition kinetics. Here, the
partition ratio is the key indicator of potential in vivo specificity
and utility. The substrate partition ratio [kcat/kinact] for a TbSMT
mechanism-based inhibitor is operationally defined as the num-
ber of inhibitor molecules that are methylated per unit time
before one enzyme molecule is irreversibly inactivated. While
the efficacy of these compounds can vary according to the
chemical design, e.g., addition of a terminal methylene cyclopro-
pane, sulfur, or fluorine substituent in the sterol side chain (Kana-
gasabai et al., 2004; Nes et al., 2012; Zhou et al., 2006), the lower
the partition ratio, the less drug is needed to kill a given enzyme
and potential toxic product release becomes null. A completely
efficient suicide substrate that targets TbSMT would generate
a partition ratio close to 1, and in so doing show desirable drug
properties of specificity and low toxicity (Walsh, 1984). In studies
of 26-FCT testedwith TbSMT, we determined that the analog is a
poor substrate for turnover; however, it irreversibly inactivated
the enzyme in a saturable way, implying that a Michaelis com-
plex forms, but partitions to favor the inactivation pathway. The
partition ratio of 1.08 shows 26-FCT to be one of the most highly
efficient mechanism-based inhibitors thus far reported in the
pharmaceutical literature.
Another critical factor in suicide substrate effectiveness for in-
hibition of ergosterol biosynthesis relates to their ability to be
accumulatedbycells and thenout-compete thenatural substrate
for acceptance by the sterol methyltransferase enzyme. In previ-
ous work with suicide substrates designed to inhibit 24-SMT in
pathogenic fungi, the compounds showed predicted in vitro ac-
tivity but failed to be taken up by the fungi (Ganapathy et al.,
2011). If these analogs are accumulated by the parasite, they
must successfully bind toTbSMTat concentrations several times
higher than the KM values of zymosterol, which correlates to its
endogenous steady-state concentration of 0.1% total sterol
yielding 145 fg/cell. In the current study, 26FL-treated cells
showed evidence for uptake and metabolism of the drug to
includeproducts ofTbSMTcatalysis. However, despite no signif-
icant change in the endogenous sterol profile except for a loss of
ergosterol, the detection of 26-fluorosterol metabolites at the
approximate level of 1% is consistent with 26-fluorozymosterolChemistry & Biology 22, 1374–1formed to a level that outcompetes the zymosterol available for
TbSMT. Notably, as the exogenous amount of 26FL supplied to
the cells was increased, providing for more endogenous 26-fluo-
rozymosterol, the cell growth fell accordingly. In contrast to our
observationswith 25-azalanosterol-treated procyclic cells where
cells at the drug IC90 generated a higher total endogenous sterol
content than treated cells at IC50 or controls (thereby suggesting
an upregulation of ergosterol biosynthesis enzymes), for the
26FL-treated cells there was no significant change in the endog-
enous sterol composition as the concentration of drug increased
from IC50 or IC90. Thus, suicide substrates of TbSMT may be
considered the ultimate physiological inhibitor for ergosterol
biosynthesis and as a potential therapeutic, because it remains
bound to the enzyme for the lifetime of the target in the cell and
its effect is specific on ergosterol formation.SIGNIFICANCE
Trypanosomes have evolved to be ruthless parasites of their
animal hosts. In this and our previous studies, we endeav-
ored to develop a new strategy to treat trypanosomiasis
that involves the inhibition of crucial enzymes in the ergos-
terol biosynthesis pathway of T. brucei. This advance,
particularly suited for specific combinations of mechanisti-
cally distinct inhibitors of TbSMT and TbSDM, can be fash-
ioned to kill rather than simply halt cell proliferation, and in
so doing overcome conventional resistance factors. Indeed,
incubating a medical azole with 25-azalanosterol paired at
their IC50 values of 1–3 mM in the growth media of T. brucei
showed synergy resulting in cell death (Haubrich et al., 2015).
This is thefirst time thatfluorinatedsterolshavebeentested
asanti-parasiticagents.Our resultsshowthepromiseof these
compounds as prodrugs, specifically 26FL, that can enter the
ergosterol biosynthesis pathway, convert to a substrate
analog of an indispensable enzyme, and through catalysis
inhibit sterol C24-methylation and cell growth. The partition
ratio for 26-FCT against TbSMT of 1.08 compares favorably
with eflonithine against ODC of approximately 3.3 (Pegg
et al., 1987), which suggests that the basis of selective and
potent anti-trypanosomal action of fluorinated inhibitors
could be the relatively slow turnover of TbSMT, which in
complex with activated analogs completely inactivates the
catalyst, as reported for eflornithine against TbODC (Wang,
1991). This constitutive property of inhibitor-protein interac-
tions may explain the minimal change in the course and
equilibrium of metabolic sequences in treated T. brucei cells
that receive the bulk amount of membrane sterol (choles-
terol) from the host. Taking into account the experiments
described and their results regarding 26-fluorinated sterols,
mechanism-based inhibitors targeting the sterol methyl-
ation enzyme might be a promising and useful additional
agent in the therapeutic armamentarium for the treatment
of sleeping sickness and other protozoan infections.EXPERIMENTAL PROCEDURES
Strain, Culture Procedures, and Cellular Sterol Analysis
T. brucei strain 427 was grown at Meharry Medical College in SDM-79 me-
dium (procyclic form) with 10% heat-inactivated fetal bovine serum (FBS)383, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1381
(Atlanta Biologicals), referred to as full-growth medium (FGM) at 27C. BSFs
originating from cells grown in rats (Sprague-Dawley male rats from Harlan
Laboratories) fed standard rat chow (PicLab Rodent diet) were cultured at
37C in HMI-9 medium supplemented with 10% heat-inactivated FBS as
previously described (Haubrich et al., 2015). HEK 293T cells were purchased
from ATCC and grown in RPMI medium supplemented with 20% heat-inac-
tivated FBS. Both cultures were maintained in a humidified atmosphere con-
taining 5% CO2. Cell counting was done with a Neubauer hemocytometer.
The procyclic form (PCF) and bloodstream form (BSF) cultures were seeded
at different densities of 2–3 3 106 cells/ml or 1 3 105 cells/ml, respectively, in
tissue-culture flasks. Cell densities were maintained in the range of 0.5–1 3
107 cells/ml for the PCF and 0.1–1 3 106 cells/ml for the BSF by re-inocula-
tion in fresh medium. Cells were harvested by centrifugation. Cell viability of
HEK cells was monitored by the trypan blue dye exclusion method. To eval-
uate the growth inhibition effect, the cells were incubated with 26FL as a 1%
(v/v) solution in DMSO in the concentration range 0–100 mM. Cells treated
with 1% DMSO alone served as controls. The concentrations of 26FL
causing 50% growth inhibition (ED50, 50% effective dose) were calculated
from dose-response curves. The selectivity of the inhibitor for the parasite
was estimated as ratio ED50 (HEK 293T/ED50 BSF) (Hoet et al., 2004). Proto-
zoan cells, collected by centrifugation, were saponified (10% KOH in meth-
anol at reflux for 30 min) and the neutral lipid obtained by dilution with water
and extraction into hexanes was analyzed by GC-MS. The protocols
involving rats were approved by the Institutional Care and Use Committee
of the Meharry Medical College.
Recovery and Analysis of Sterols from Cultured Cells
PCF and BSF cultures and HEK cells were harvested at growth arrest in the
presence or absence of 26FL at the IC50 and IC90 concentrations of the com-
pound for T. brucei cells or 30 mM compound for HEK cells. Cell pellets were
split with an internal standard of 5a-cholestane added to one of the cell pellets.
Cells were saponified with 10% methanolic KOH and extracted with hexanes.
The neutral lipids were analyzed by GC-MS against cholesterol as a chromato-
graphic reference. Mass spectral data were compared with those obtained
from authentic standards.
Enzyme Assay and Product Analysis
The activity assays and analysis of enzyme-generated products were per-
formed in the manner of Zhou et al. (2007). A brief description of these proto-
cols using the cloned TbSMT is provided in Supplemental Experimental
Procedures.
Mechanism-Based Inactivation Experiments
The soluble enzyme fraction containing TbSMT (100,000 3 g supernatant
fraction, 75 mg, 600 ml) in the standard assay buffer was incubated at 35C
for up to 10 min at 0 mM (control), 25, 50 and 100 mM 26-fluorocholesta-
5,7,24-trienol at 2, 5, 8 and 10 min, and the samples placed in test tubes
pre-cooled with dry ice/ethanol to prevent catalysis. The samples were
then thawed on ice, and the unbound inhibitor and SAM removed by
repeated filtration using a Centricon (YM-10 membrane). Following treat-
ment, the remaining enzyme activity was measured by comparison with
the enzymatic activity of assays carried out under the standard assay condi-
tions with saturated concentrations of zymosterol (100 mM) paired with
3H-SAM (100 mM). The logarithmic percentage of enzyme activity was plotted
against the incubation time of the enzyme-inhibitor mixture to determine the
half-life (T½) of inactivation as previously described (Marshall, 2001; Nes
et al., 2008). Chemical labeling of TbSMT by 26-fluorosterol was carried
out using 3 mg/ml in standard lysate assay in overnight incubation. The abor-
tive product covalently bound to the enzyme was released from the enzyme-
sterol complex by saponification, and the resulting neutral lipids composed
of steroidal monols and diols (from ester formation in the active site) analyzed
by GC-MS.
Compound Synthesis
The synthetic scheme (Figure S4) and detailed procedures for the preparation
and characterization of the 26-fluorosterols tested in this study are described
in Supplemental Experimental Procedures.1382 Chemistry & Biology 22, 1374–1383, October 22, 2015 ª2015 ESUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.chembiol.2015.08.017.
AUTHOR CONTRIBUTIONS
W.D.N. and M.C. designed the experiments; D.J.L., P.P., U.K.S., M.B.M., and
B.A.H. performed the kinetic and growth experiments; M.B.M, and D.J.L.
generated the standards and prepared the fluorinated compounds; W.D.N.
and M.C. analyzed the data; W.D.N. wrote the manuscript; D.J.L., P.P.,
U.K.S., M.B.M., B.A.H., M.C., and W.D.N. edited the manuscript.
ACKNOWLEDGMENTS
This work was supported by grants from the NIH (R21AI 119782) and National
Science Foundation (MCB-0929212) to W.D.N. and from the NIH (GM081146)
to M.C. The involvement of Alicia Howard with the art in the graphical abstract
is appreciated.
Received: June 1, 2015
Revised: August 20, 2015
Accepted: August 28, 2015
Published: October 22, 2015
REFERENCES
Andrews, K.T., Fisher, G., and Skinner-Adams, T.S. (2014). Drug repurposing
andhumanparasiticdiseases. Intern. J.Parasitol.DrugsDrugResist.4, 95–111.
Barrett, M.P. (2010). Potential new drugs for human African trypanosomiasis:
some progress at last. Curr. Opin. Infect. Dis. 23, 603–608.
Barrett, M.P., Vincent, I.M., Burchmore, R.J., Kazibwe, A.J., and Matovu, E.
(2011). Drug resistance in human African trypanosomiasis. Future Microbiol.
6, 1037–1047.
Bruegemeier, R.W., Hackett, J.C., and Diaz-Cruz, E.S. (2005). Aromatase in-
hibitors in the treatment of breast cancer. Endocr. Rev. 26, 331–345.
Chitanga, S., Marcotty, T., Namangala, B., Van den Bossche, P., Abbeele,
J.V.D., and Delespaux, V. (2011). High prevalence of drug resistance in animal
trypanosomeswithout a historyof drugexposure.PlosNegl. Trop.Dis.5, e1454.
Ferrins, L., Rahmani, R.S., and Baell, J.B. (2013). Drug discovery and human
African trypanosomiasis: a disease less neglected? Future Med. Chem. 5,
1801–1841.
Fugi,M.A., Gunasekera, K.,Ochsenreiter, T., Guan, X.,Wenk,M.R., andMaser,
P. (2014). Genome profiling of sterol synthesis shows convergent evolution in
parasites and guides chemotherapeutic attack. J. Lipid Res. 55, 929–938.
Ganapathy, K., Kanagasabai, R., Nguyen, T.T.M., and Nes, W.D. (2011).
Purification, characterization, and inhibition of sterol C24-methyltransferase
from Candida albicans. Arch. Biochem. Biophys. 505, 194–201.
Gigante, F., Kaiser, M., Brun, R., and Gilbert, I.H. (2009). SAR studies on azas-
terols as potential anti-trypanosomal and anti-leishmanial agents. Bioorg.
Med. Chem. 17, 5950–5961.
Gilbert, I.H. (2013). Drug discovery for neglected diseases: molecular target-
based and phenotypic approaches. J. Med. Chem. 56, 7719–7726.
Gros, L., Lorente, S.O., Jimenez, C.J., Yardley, V., Rattray, L., Wharton, H.,
Little, S., Croft, S.L., Ruiz-Perez, L.M., Gonzlez-Pacanowska, D., and
Gilbert, I.H. (2006). Evaluation of azasterols as anti-parasites. J. Med. Chem.
49, 6094–6103.
Gunatilleke, S.S., Calvet, C.M., Johnston, J.B., Chen, C.-K., Erenburg, G., Gut,
J., Engel, J.C.,Ang,K.K.H.,Mulvaney, J.,Chen,S., et al. (2012). Diverse inhibitor
types targeting the Trypanosoma cruzi CYP51. Plos Negl. Trop. Dis. 6, e1736.
Hargrove, T.Y., Liu, J., Nes, W.D., Waterman, M.R., and Lepesheva, G.I.
(2011). Substrate preferences and catalytic parameters determined by struc-
tural characteristics of sterol 14a-demethylase CYP51 from Leishmania infan-
tum. J. Biol. Chem. 286, 26838–26848.lsevier Ltd All rights reserved
Hargrove, T.Y., Wawrzak, Z., Liu, J., Waterman, M.R., Nes, W.D., and
Lepesheva, G.I. (2012). Structural complex of sterol 14a-demethylase
(CYP51) with 14a-methylenecyclopropyl-D7-24,25-dihdrolanosterol. J. Lipid
Res. 53, 311–320.
Haubrich, B.A., Singha, U.K., Miller, M.B., Nes, C.R., Anyatonwu, H.,
Lecordier, L., Patkar, P., Leaver, D.J., Villalta, F., Vanhollebeke, B., et al.
(2015). Discovery of an ergosterol-signaling factor that regulates
Trypanosoma brucei growth. J. Lipid Res. 56, 331–341.
Heby, O., Roberts, S.C., and Ullman, B. (2003). Polyamine biosynthetic en-
zymes as drug targets in parasitic protozoa. Biochem. Soc. 31, 415–419.
Hoet, S., Opperdoes, F., Brun, R., and Quentin-Leclercq, J. (2004). Natural
products active against African trypanosomes: a step towards new drugs.
Nat. Prod. Rep. 21, 353–364.
Kanagasabai, R., Zhou, W., Liu, J., Nguyen, T.T.M., Veeramachaneni, P., and
Nes, W.D. (2004). Disruption of ergosterol biosynthesis, growth and the
morphological transition inCandida albicans by sterol methyltransferase inhib-
itors containing sulfur in the sterol side chain. Lipids 39, 737–746.
Kauffman, J.M.,Westerman, P.W., andCarey,M.C. (2000). Fluorocholesterols,
in contrast to hydroxycholesterols, exhibit interfacial properties similar to
cholesterol. J. Lipid Res. 41, 991–1003.
Lepesheva, G.I., andWaterman,M.R. (2011). Sterol 14a-demethylase (CYP51)
as a therapeutic target for human trypanosomiasis and leishmaniasis. Curr.
Top. Med. Chem. 11, 2060–2071.
Lepesheva, G.I., Ott, R.D., Hargrove, T.Y., Kleshchenko, Y.Y., Schuster, I.,
Nes,W.D., Hill, G.C., Villalta, F., andWaterman, M.R. (2007). Sterol 14a-deme-
thylase as a potential target for antitrypanosomal therapy: enzyme inhibition
and parasite cell growth. Chem. Biol. 14, 1283–1293.
Liu, J., and Nes, W.D. (2009). Steroidal triterpenes: design of substrate-based
inhibitors of ergosterol and sitosterol synthesis. Molecules 14, 4690–4706.
Liu, J., Ganapathy, K., Wywial, E., Bujmicki, J.M., Nwogwugwu, C.A., and Nes,
W.D. (2011). Effect of substrate features and mutagenesis of active site tyro-
sine residues on the reaction course catalyzed by Trypanosma brucei sterol
C24-methyltransferase. Biochem. J. 439, 413–422.
Lorente, S.O., Rodrigues, J., Jime´nez Jime´nez, C., Joyce-Menekse, M.,
Rodrigues, C., Croft, S.L., Yardley, V., de Luca-Fradley, K., Ruiz-Pe´rez,
L.M., Urbina, J., et al. (2004). Novel azasterols as potential agents for treatment
of leishmaniasis and trypanosomiasis. Antimicrob. Agents Chemother. 48,
2937–2950.
Lovieno, A., Miller, D., Ledee, D.R., and Alfonso, E.C. (2014). Cysticidal activity
of antifungals against different genotypes of Acanthamoeba. Antimicrob.
Agents Chemother. 58, 5626–5628.
Marshall, J.A. (2001). Studies on the Enzymology of Sterol Methyltransferase
From Saccharomyces Cerevisiae, Doctoral Dissertation (Texas Tech
University), pp. 1–95.
Matsumori, N., Kasai, Y., Oishi, T., Murata, M., and Nomura, K. (2008).
Orientation of fluorinated cholesterol in lipid bilayers analyzed by 19F tensor
calculation and solid-state NMR. J. Am. Chem. Soc. 130, 4757–4766.
Nes, W.D. (2011). Biosynthesis of cholesterol and other sterols. Chem. Rev.
111, 6423–6451.
Nes, W.D., Xu, S., and Haddon, W.F. (1988). Evidence for similarities and dif-
ferences in the biosynthesis of fungal sterols. Steroids 53, 533–558.
Nes, W.D., McCourt, B.S., Zhou, W.-X., Ma, J., Marshall, J.A., Peek, L.-A., and
Brennan, M. (1998). Overexpression, purification, and stereochemical studies
of the recombinant (S)-adenosyl-L-methionine: D24(25) -to D24(28)-sterol meth-
yltransferase from Saccharomyces cerevisiae. Arch. Biochem. Biophys. 353,
297–311.
Nes, W.D., Song, Z., Dennis, A.L., Zhou, W., Nam, J., and Miller, M. (2003).
Biosynthesis of phytosterols: kinetic mechanism for the enzymatic C-methyl-
ation of sterols. J. Biol. Chem. 278, 34505–34516.
Nes, W.D., Jayasimha, P., and Song, Z. (2008). Yeast sterol C24-methyltrans-
ferase: role of highly conserved tyrosine in catalytic competence studied by
site-directed mutagenesis and thermodynamic analysis. Arch. Biochem.
Biophys. 477, 316–323.Chemistry & Biology 22, 1374–1Nes, C.R., Singha, U.K., Liu, J., Villalta, F., Waterman, M.R., Lepesheva, G.I.,
Chaudhuri, M., and Nes, W.D. (2012). Novel sterol metabolic network of
Trypanosoma brucei procyclic and bloodstream forms. Biochem. J. 443,
267–276.
Patkar, P., Haubrich, B.A., Qi, M., Nguyen, T.T., Thomas, C.D., and Nes, W.D.
(2013). C-24-methylation of 26-fluorocycloartenols by recombinant sterol
C24-methyltransferase from soybean: evidence for channel switching and its
phylogenetic implications. Biochem. J. 456, 253–262.
Pegg, A.E., McGovern, K.A., andWiest, L. (1987). Decarboxylation of a-difluor-
oethylornithine by ornithine decarboxylase. Biochem. J. 241, 305–307.
Pink, R., Hudson, A., Mouries, M.-A., and Bendig, M. (2005). Opportunities and
challenges in anti-parasitic drug discovery. Nat. Rev. Drug Discov. 4, 727–740.
Porta, E.O.J., Carvalho, P.B., Avery, M.A., Tekwani, B.L., and Labadie, G.R.
(2014). Click chemistry decoration of amino sterols as promising strategy to
develop new leishmanicidal drugs. Steroids 79, 28–36.
Poulin, R., Lu, L., Ackerman, B., Bey, P., and Pegg, A.E. (1992). Mechanism of
the irreversible inactivation of mouse ornithine decarboxylase by a-difluoro-
methylornithine. J. Biol. Chem. 267, 150–158.
Rahman, M.D., and Pascal, R.A., Jr. (1990). Inhibitors of ergosterol biosyn-
thesis and growth of the trypanosomatid protozoan Crithidia fasiculata.
J. Biol. Chem. 265, 4989–4996.
Roberts, C.W., Mcleod, R., Rice, D.W., Ginger, M., Chance, M.L., and Goad,
L.J. (2003). Fatty and sterol metabolism: potential antimicrobial targets in api-
complexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol.
126, 129–142.
Rodriguez, R.J., and Parks, L.W. (1981). Physiological response of
Saccharomyces cerevisiae to 15-azasteroid-mediated growth inhibition.
Antimicrob. Agents Chemother. 20, 184–189.
Sardari, S., Mori, Y., Kurosawa, T., and Daneshtalab, M. (2003). Modulatory ef-
fect of cAMP on fungal ergosterol level and inhibitory activity of azole drugs.
Can. J. Microbiol. 49, 344–349.
Trzaskos, J.M., Magolda, R.L., Favata, M.F., Fischer, R.T., Johnson, P.R.,
Chen, H.W., Ko, S.S., Leonard, D.A., and Gaylor, J.L. (1993). Modulation of
3-hydroxy-3-methylglutaryl-CoA reductase by 15a-fluorolanst-7-en-3b-ol.
J. Biol. Chem. 268, 22591–22599.
Van Den Abbeele, J., Claes, Y., Van Bockstacle, D., Le Ray, D., and
Coosemans, M. (1999). Trypanosoma brucei spp. Development in the tsetse
fly: characterization of the post-mesocyclic stages in the foregut and probos-
cis. Parasitology 118, 469–478.
Walsh, C.T. (1984). Suicide substrates, mechanism-based enzyme inactiva-
tors: recent developments. Annu. Rev. Biochem. 53, 494–535.
Wang, C.C. (1991). A novel suicide inhibitor strategy for antiparasitic drug
development. J. Cell Biochem. 45, 49–53.
Wang, J., Liu, J., Song, Z., and Nes, W.D. (2008). Sterol C24-methyltransfer-
ase: mechanistic studies of the C-methylation reaction with 24-fluorocycloar-
tenol. Bioorg. Med. Chem. Lett. 18, 232–235.
World Health Organization. (2013). Trypanosomiasis, Human African Sleeping
Sickness, Accessed July 14, 2013. http://www.who.int/trypanosomiasis_
african/en/index.html.
Xu, S., Norton, R.A., Crumley, F.G., and Nes, W.D. (1988). Comparison of the
chromatographic properties of sterols, select additional steroids and triterpe-
noids: gravity-flow liquid chromatography, thin-layer chromatography, gas-
liquid chromatography, and high performance liquid chromatography.
J. Chromatogr. 452, 377–398.
Zhou,W., Lepesheva,G.I.,Waterman,M.R., andNes,W.D. (2006).Mechanistic
analysis of a multiple product sterol methyltransferase implicated in ergosterol
biosynthesis in Trypanosoma brucei. J. Biol. Chem. 281, 6290–6296.
Zhou, W., Cross, A.M., and Nes, W.D. (2007). Cholesterol import fails to pre-
vent catalyst-based inhibition of ergosterol synthesis and cell proliferation of
Trypanosoma brucei. J. Lipid Res. 48, 665–673.
Zundel, M., Nambiar, K.P., Boswell, G., and Bloch, K. (1989). 6-
Fluorocholesterol as a growth factor for the yeast mutant GL7. Biochemistry
28, 5161–5164.383, October 22, 2015 ª2015 Elsevier Ltd All rights reserved 1383
